Key Insights

Highlights

Success Rate

72% trial completion

Published Results

116 trials with published results (11%)

Research Maturity

347 completed trials (33% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

13.0%

135 terminated out of 1037 trials

Success Rate

72.0%

-14.5% vs benchmark

Late-Stage Pipeline

1%

11 trials in Phase 3/4

Results Transparency

33%

116 of 347 completed with results

Key Signals

116 with results72% success135 terminated

Data Visualizations

Phase Distribution

946Total
Not Applicable (64)
Early P 1 (40)
P 1 (729)
P 2 (102)
P 3 (4)
P 4 (7)

Trial Status

Completed347
Recruiting271
Unknown148
Terminated135
Active Not Recruiting70
Not Yet Recruiting34

Trial Success Rate

72.0%

Benchmark: 86.5%

Based on 347 completed trials

Clinical Trials (1037)

Showing 20 of 20 trials
NCT06487858Phase 1TerminatedPrimary

A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors

NCT03560882Phase 1Active Not Recruiting

A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies

NCT05985161Phase 2Recruiting

A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors

NCT07489378Recruiting

NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors

NCT07570563Phase 1Recruiting

Clinical Study of the Safety and Efficacy of QH101 Cell in Patients With Malignant Tumors.

NCT06475300Phase 2Recruiting

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

NCT05206942Not ApplicableSuspendedPrimary

Serial Ultrasound of Solid Tumor Lesions to Detect Early Response to Cancer Immunotherapy

NCT05919264Phase 1Recruiting

FOG-001 in Locally Advanced or Metastatic Solid Tumors

NCT02332668Phase 1Recruiting

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

NCT06619587Phase 1RecruitingPrimary

A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors

NCT06895681Not Yet RecruitingPrimary

UCSF Biobank for Hereditary Cancers and Tumor-Associated Mutations

NCT05645523Early Phase 1RecruitingPrimary

Indocyanine Green (ICG) Guided Sentinel Lymph Node Mapping for Pediatric Visceral Solid Tumors

NCT06349837Phase 1RecruitingPrimary

Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors

NCT06441331Phase 1Recruiting

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

NCT07419581Not ApplicableNot Yet Recruiting

A Study of Freeze-Dried Miracle Fruit (MiraBurst) on Participants Receiving Cancer Treatment

NCT04084067Phase 1Recruiting

Indocyanine Green (ICG) Guided Tumor Resection

NCT06305247Phase 1Recruiting

A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours

NCT07556276Phase 1RecruitingPrimary

Study of CMTS1215 Injection in Patients With Solid Tumors

NCT06094426Early Phase 1TerminatedPrimary

Autologous Tumor Infiltrating Lymphocyte Injection for the Treatment of Advanced Solid Tumors

NCT06145802Not ApplicableWithdrawnPrimary

Clinical Study of Autologous Tumor Infiltrating Lymphocyte Injection (GT316) in the Treatment of Advanced Solid Tumors (Gynecological Tumors)

Scroll to load more

Research Network

Activity Timeline